ATE256196T1 - Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten - Google Patents

Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten

Info

Publication number
ATE256196T1
ATE256196T1 AT98929010T AT98929010T ATE256196T1 AT E256196 T1 ATE256196 T1 AT E256196T1 AT 98929010 T AT98929010 T AT 98929010T AT 98929010 T AT98929010 T AT 98929010T AT E256196 T1 ATE256196 T1 AT E256196T1
Authority
AT
Austria
Prior art keywords
genome
eukaryontic
virus
vectors containing
packaging region
Prior art date
Application number
AT98929010T
Other languages
English (en)
Inventor
Duncan L Mcvey
Douglas E Brough
Mohammed Zuber
Imre Kovesdi
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Application granted granted Critical
Publication of ATE256196T1 publication Critical patent/ATE256196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
AT98929010T 1997-06-09 1998-06-09 Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten ATE256196T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4907297P 1997-06-09 1997-06-09
US7222298P 1998-01-22 1998-01-22
PCT/US1998/012158 WO1998056937A2 (en) 1997-06-09 1998-06-09 Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus

Publications (1)

Publication Number Publication Date
ATE256196T1 true ATE256196T1 (de) 2003-12-15

Family

ID=26726837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98929010T ATE256196T1 (de) 1997-06-09 1998-06-09 Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten

Country Status (6)

Country Link
US (2) US6440728B1 (de)
EP (1) EP0996735B1 (de)
AT (1) ATE256196T1 (de)
AU (1) AU8067698A (de)
DE (1) DE69820450T2 (de)
WO (1) WO1998056937A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69831417T2 (de) 1997-09-23 2006-06-22 Genvec, Inc. Duale selektionkassette und sie enthaltende plasmide
EP1248851A2 (de) * 1999-12-07 2002-10-16 Genethon III Fuer den transfer in zielzellen bestimmte vektoren, die von dem genom von hunde-adenoviren abgeleitet sind
EP1118670A1 (de) * 1999-12-07 2001-07-25 Genethon III Hunde-Adenovirusvektoren für den Transfer von Genen in Zielzellen
AU2001234980A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
IT1318704B1 (it) * 2000-09-22 2003-08-27 Consorzio Interuniversitario P Vettori chimerici e loro uso per il trasferimento di geni eterologhi.
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
FR2820146B1 (fr) * 2001-01-29 2003-06-27 Centre Nat Rech Scient Procede d'obtention de cellules d'encapsidation fortement productrices de retrovirus par elimination, au sein de la culture, des cellules permissives a l'infection par le retro virus produit
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
EP1649028B1 (de) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviralevektoren-basierte impfstoffe
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
EP1737885A2 (de) 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von adenoviralen vektoren zur erzeugung einer immunantwort
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
CN103038343A (zh) 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
SG187784A1 (en) * 2010-08-16 2013-03-28 Salk Inst For Biological Studi Adenoviral assembly method
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CA2957737A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
JP7427584B2 (ja) 2017-10-13 2024-02-05 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクターｉｇｍ応答を減弱化するための方法および組成物
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
US20200390718A1 (en) 2019-05-28 2020-12-17 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination

Also Published As

Publication number Publication date
DE69820450T2 (de) 2004-05-27
EP0996735B1 (de) 2003-12-10
WO1998056937A3 (en) 1999-03-11
WO1998056937A2 (en) 1998-12-17
EP0996735A2 (de) 2000-05-03
US7070930B2 (en) 2006-07-04
US6440728B1 (en) 2002-08-27
AU8067698A (en) 1998-12-30
US20030170899A1 (en) 2003-09-11
DE69820450D1 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
ATE256196T1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
ATE466931T1 (de) Verbesserte adenovirusvektoren
AU9338598A (en) Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
ATE270342T1 (de) Endosomolytisch wirksame partikel
DE60215461D1 (de) Serpin von bifidobakterien
AU9254801A (en) Methods for treating cell proliferative disorders and viral infections
IL135776A0 (en) Recombinational cloning using nucleic acids having recombination sites
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DK0843731T3 (da) Adenovirusvektorer til genterapi
IL117194A0 (en) Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them
ES2101486T3 (es) Sintesis de riboflavina en levaduras.
ES2079348T3 (es) Procedimiento de estabilizacion de un plasmido contenido en una cepa bacteriana y cepa obtenida.
IL115432A0 (en) Viral vectors and their uses in gene therapy
AU2002320773A1 (en) Vector for site-specific integration of heterologous dna sequences into the rdn a sites of methylotrophic yeasts
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
ES2171657T3 (es) Vector de dna recombinante para terapia genica.
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
RU94030484A (ru) Плазмида, вектор, микроорганизм, лактобациллы, применение плазмиды и вектора

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties